Seminars in Reproductive Medicine 2003: Vol 21 Index

7 Pages·2003·1.6 MB·English

Author Index
VOLUME 21, 2003
Adamson, David, 223 Garcia-VelascJou,a n A., 165 Mol, Ben W., 9, 17
Arici, Aydin, 109, 135, 165 Garrido, Nicolas, 183 Moran, Carlos, 295
Azziz, Ricardo, 295 Gell, Jennifer S., 375
Giudice, Linda C., 119 Neithardt, Adrienne B., 285
Barnes, Randall B., 285 Groll, Jeremy M., 27
Bossuyt, Patrick M.M., 17 Gurates, Bilgin, 125 Olive, David L., 209
Bradshaw, Karen D., 327, 339, 353 Guzick, David, 309 Osteen, Kevin G., 155
Bruner-Tran, Kaylon L., 155
Bulun, Serdar E., 125 Habbema, J.D.F., 39 Pellicer, Antonio, 183
Hastings, Julie M., 255 Pirard, Céline, 235
Carr, Bruce R., 1, 107, 263, 325 Heroux, Kimberly, 389
Collins, John A., 3, 49, 95 Hill, Joseph A., 243 Remohi, José, 183
Coutifaris, Christos, 265, 317 Hoffman, Barbara, 353 Rier, Sherry, 145
Hughes, Edward G., 55 Rychlik, Daniel, 277
Davis, O.K., 65
SchlesselmaJanm,es J., 95
Daya, Salim, 73 Jabara, Sami, 317
Seli, Emre, 135
Debrock, Sophie, 243 Jadoul, Pascale, 235 Simon, Carlos, 183
D’Hooghe, Thomas M., 243
Smets, Mireille, 235
Donnez, Jacques, 235 Kakarla, Nirupama, 339 Spaczynski, Robert Z., 193
Driscoll, Deborah A., 301 Kashyap, S., 65 Squifflet, Jean, 235
Duleba, Antoni J., 193 Kass-Wolff, Jane, 329 Sukalich, Sara, 309
Kennedy, Stephen, 111
Sulak, Patricia J., 399
Ehrmann, David A., 277
Eijkemans, M.J.C., 39 Land, Jolande A., 9 Van Steirteghem, André, 49
Evers, Johannes L.H., 9, 17 Legro, Richard S., 267 Van Voorhis, Bradley J., 85
Lijmer, Jeroen G., 17
Fauser, B.C.J.M., 39 Liu, James H., 5 Wilson, Ellen E., 329
Fazleabas, Asgerally T., 255 Witz, Craig A., 173
Foster, Warren G., 145 Meuleman, Christel, 243
Fritz, Marc A., 27 Minjarez, Debra A., 363 Yeaman, Grant R., 155
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: [phone].

Subject Index
VOLUME 21, 2003
Absolute numbers, in randomized clinical trials (RCT), Cadherins, endometriosis and, 175-178
clinical research vs. medical practice, 55-64 CA-125 marker, endometriosis diagnosis, 193-202
Acanthosis nigricans, polycystic ovary syndrome (PCOS) Cardiovascular health
and, 271-273 contraception for medically ill adolescent patients, 390-398
Acne, polycystic ovary syndrome (PCOS), pharmacologic polycystic ovary syndrome (PCOS) and, 309-314
treatment, 277-282 Case control studies
Acquired immunodeficiency syndrome (AIDS), in adolescent causation study guidelines and, 73-83
patients, 407-408 diagnostic studies using, 20-25
Adolescent patients. See a/so Pediatric gynecology Causation studies, guidelines for, 73-83
abnormal bleeding in, 363-372 cDNA microarray analysis, endometriosis research and,
contraceptive choices for chronically ill patients, 389-398 259-260
delayed puberty and amenorrhea, 353-361 Cell adhesion molecules (CAMs), endometriosis and,
polycystic ovary syndrome (PCOS), 301-306 173-179
pubertal developmental disorders, 339-350 apoptosis pathways, 168-170
sexually transmitted disease (STD) in, 399-411 Cervicitis, abnormal bleeding in adolescents and, 365-370
Adrenal hyperplasia, in polycystic ovary syndrome (PCOS) Chlamydia, in adolescent patients, 402-403
patients, 295-299 Chlamydia antibody test (CAT), evidence-based diagnosis
Amenorrhea, delayed puberty and, 353-361 and, 9-14
Androgen excess. See Hyperandrogenism Clinical research. See a/so Randomized clinical trials (RCT)
Androgen receptor antagonists, for polycystic ovary syndrome diagnostic research, evidence-based strategies, 9-14
(PCOS) patients, 289-291 evidence-based search strategies, 5-8
Angiongenesis inhibitors, endometriosis therapy using, medical therapy for endometriosis and, 209-218
212-218 randomized clinical trials (RCT) and medical practice vs.,
Animal models, endometriosis research, 150-151, 255-260 55-64
Anovulation systematic review and meta-analysis of, 95-104
abnormal bleeding in adolescents, 363-372 Clomiphene citrate therapy, ovulation induction, outcome
clomiphene citrate therapy, outcome predictions, 39-46 predictions, 39-46
polycystic ovary syndrome (PCOS), 267-273 Coagulation disorders, polycystic ovary syndrome (PCOS)
Antiandrogens, polycystic ovary syndrome (PCOS), hirsutism patients and, 311-314
diagnosis and management, 285-291 Cohort studies
Apoptosis, endometriosis pathogenesis and, 165-170 causation study guidelines, 73-83
Aromatase, endometriosis pathophysiology, 125-132 diagnostic studies using, 20-25
Aromatase inhibitors Condom use, sexually transmitted disease (STD) in
endometriosis pathophysiology, 125-132 adolescents and, 399-411
endometriosis therapy using, 212-218 Condyloma acuminata
Assisted reproduction therapy (ART), intracytoplasmic abnormal bleeding in adolescents and, 366-370
sperm injection vs. in vitro fertilization, evidence- in pediatric patients, 336-337
based research, 49-54 Confounding variables, causation study guidelines, 73-83
Autoantibodies, endometriosis and, 137-141 Contraception. See a/so Oral contraceptives
for medically ill adolescent patients, 389-398
Bcl-2/bax genes, apoptosis and endometriosis pathogenesis, sexually transmitted disease (STD) in adolescents and,
165-170 399-411
Bias, causation study guidelines and, 73-83 Contrasexual development, in pediatric patients, 349-350
Bioinformatics, endometriosis research and, 260 Coronary heart disease (CHD)
Blood dyscrasia, abnormal bleeding in adolescents and, contraception for medically ill adolescent patients,
365-370 390-398
Breast disease, contraception for medically ill adolescent polycystic ovary syndrome (PCOS) and risk of, 309-314
patients and risk of, 390-398 prognosis studies, literature evaluation for, 27-35
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel: [phone].
SEMINARS IN REPRODUCTIVE MEDICINE/VOLUME 21, NUMBER 4 2003
Cost-effectiveness, economics studies evaluation, 85-92 surgical management of, pre- and post-surgical protocols,
Cytokines 235-240
endometriosis pathophysiology and, 135-141 uterine and ovarian function, 183-189
matrix metalloproteinases, endometriosis pathophysiology, Environmental contaminants
155-160 endometriosis and, 145-151
matrix metalloproteinases, endometriosis pathophysiology,
Danazol, endometriosis therapy using, 209-218 155-160
Delayed puberty, amenorrhea and, 353-361 Estradiol, endometriosis pathophysiology, 125-132
Diabetes mellitus, contraception for medically ill adolescent Estrogen
patients, 390-398. See also Type 2 diabetes mellitus endometriosis pathophysiology, 125-132
Diagnostic studies endometriosis therapy using, 212-218
characteristics of, 17-25 matrix metalloproteinases, endometriosis pathophysiology,
endometriosis, 193-202 155-160
evidence-based guidelines for, 9-14 Estrogen receptor (ERB), endometriosis research and,
pediatric gynecology, 329-337 255-260
polycystic ovary syndrome (PCOS), 267-273 Estrone, endometriosis pathophysiology, 125-132
21-hydroxylase-deficient nonclassic adrenal hyperplasia, Eutopic endometrium
differential diagnosis, 295-299 apoptosis and endometriosis pathogenesis, 165-170
Diagnostic testing, causation study guidelines and, 73-83 endometriosis and function of, 186-189
Differential diagnoses gene/protein expression, 122-123
endometriosis, 193-202 research issues involving, 255-260
evidence-based strategies for, 9-14 Evidence-based research guidelines
polycystic ovary syndrome (PCOS), 267-273 diagnostic issues, 9-14
21-hydroxylase-deficient nonclassic adrenal hyperplasia prognosis studies, 27-35
and, 295-299 therapeutic options and, 5-8
Dioxins/dioxin-like polychlorinated biphenyls, endometriosis in vitro fertilization trials, 49-54
pathogenesis and, 145-151 Exercise/dieting, abnormal bleeding in adolescents and,
DNA markers, endometriosis genetics, 111-117 371-372
Ductal system development, Miillerian anomalies, 377-387 Extracellular matrix (ECM), endometriosis and
Dyslipidemia apoptosis pathways, 165-17
contraception for medically ill adolescent patients, cell adhesion molecules (CAMs), 173-179
390-398
polycystic ovary syndrome (PCOS) and cardiovascular Familial male precocious puberty, pathophysiology, 348-349
health, 309-314 Fas/fas ligands, apoptosis and endometriosis pathogenesis,
165-170
Economics studies, evaluation of, 85-92 Femal genital anatomy
Ectopic endometrium delayed puberty and defects in, 359-361
gene/protein expression, 122-123 Miillerian anomalies, 375-387
research issues involving, 255-260 in pediatric patients, 329-333
Ectopic hormone production, pubertal developmental pubertal developmental disorders and, 340-343
disorders and, 349 Fertility drugs, ovarian cancer risk and, 65-71
Embryo status, in endometriosis, 183-189
Endocrine system Genetics studies. See a/so Proteomics
endometriosis pathophysiology and, 135-141 apoptosis and endometriosis pathogenesis, 165-170
environmental contaminants and endometriosis, 145-151 endometriosis, positional cloning, 111-117
Endometriomas, surgical management of, 223-230 Genital herpes, in adolescent patients, 405-406
Endometriosis Genital human papillomavirus, in adolescent patients,
apoptosis and pathogenesis of, 165-170 406-407
cell-adhesion molecules, 173-179 Genomics, endometriosis pathogenesis, 119-123
differential diagnosis, 193-202 Gestrinone, endometriosis therapy using, 211-218
environmental dioxins and, 145-151 Glucocorticoids, for polycystic ovary syndrome (PCOS)
future research issues, 255-260 patients, 289-291
genetics and positional cloning, 111-117 GnRH agonists/antagonists
hormonal factors in, 125-132 endometriosis therapy using, 211-218
immune/endocrine system interaction, 135-141 for polycystic ovary syndrome (PCOS) patients, 289-291
matrix metalloproteinases and, 155-160 Gonadotropin-dependent precocious puberty, 345-347
medical therapy, 209-218 Gonadotropin-independent precocious puberty, 347-349
pathogenesis, genomic studies, 119-123 Gonadotropin-releasing hormone (GnRH), pubertal
subfertility and, 243-251 developmental disorders, 339-350
surgical management of, 223-230 Gonorrhea, in adolescent patients, 403-404
SUBJECT INDEX 1-5
Hair removal, polycystic ovary syndrome (PCOS), hirsutism in polycystic ovary syndrome (PCOS) patients, 279-283,
diagnosis and management, 285-291 317-323
Hirsutism, polycystic ovary syndrome (PCOS) surgical management of endometriosis and, 223-230
adolescent patients, 301-306 uterine and ovarian function with endometriosis and,
diagnosis and management, 285-291 183-189
pharmacologic treatment, 277-282 Inflammatory disease, endometriosis research and, 255-260
Hormone function Inheritance studies, polycystic ovary syndrome (PCOS),
delayed puberty and, 353-361 298-299
endometriosis pathophysiology and, 125-132 Insulin resistance
medical therapy for endometriosis and, 209-218 polycystic ovary syndrome (PCOS), 267-273
polycystic ovary syndrome (PCOS), adolescent patients, cardiovascular health and, 309-314
301-306 polycystic ovary syndrome (PCOS), pharmacologic
pubertal developmental disorders, 339-350 treatment, 277-282
Human immunodeficiency virus (HIV), in adolescent Integrins, endometriosis and, 174-178
patients, 407-408 “Intent to treat” analysis, randomized clinical trials (RCT)
Humoral immune response, endometriosis and, 137-141 and clinical research vs., 55-64
21-Hydroxylase-deficient nonclassic adrenal hyperplasia Intracytoplasmic sperm injection (ICSI), vs. in vitro
(NCAR), polycystic ovary syndrome (PCOS), fertilization, evidence-based research, 49-54
differential diagnosis, 295-299 In vitro fertilization/embryo transfer (IVF-ET)
17B-Hydroxysteroid dehydrogenase (HSD) type 2, clinical trials, evidence-based research guidelines, 49-54
endometriosis pathophysiology, 125-132 economics studies evaluation, 85—92
Hyperandrogenism, polycystic ovary syndrome (PCOS), endometriosis pathogenesis, 119-123
267-273 ovarian and uterine function in endometriosis and,
adrenal hyperplasia and, 295-299 183-189
hirsutism diagnosis and management, 285-291 ovarian cancer risk and, 65-71
Hypercoagulation, contraception for medically ill adolescent in polycystic ovary syndrome (PCOS) patients, 317-323
patients, 390-398
Hypergonadotropic hypogonadism, delayed puberty and, Kallmann syndrome, delayed puberty and, 355-361
356-361 Klinfelter’s syndrome, delayed puberty and, 357-361
Hyperprolactinemia, abnormal bleeding in adolescents and,
371-372 Labial adhesions, in pediatric patients, 333-335
Hypertension Laparoscopy
contraception for medically ill adolescent patients, endometriosis diagnosis, 193-202
390-398 evidence-based diagnostic strategies using, 9-14
in polycystic ovary syndrome (PCOS) patients, 310-314 Lateral fusion, Miillerian anomalies and, 385-387
Hypogonadotropic hypogonadism, delayed puberty and, Likelihood ratios, in diagnostic studies, 17-25
355-361 Literature resources
Hypothalamic-pituitary-ovarian (HPO) axis evaluation of, for prognosis strategies, 27-35
abnormal bleeding in adolescents and, 363-372 evidence-based search strategies, 5-8
precocious puberty diagnosis and pathophysiology, ovarian cancer risk and fertility drugs, evaluation of
339-350 literature on, 65-71
Hypothyroidism, abnormal bleeding in adolescents and, systematic review and meta-analysis of, 95-104
371-372 Luteinizing hormone, polycystic ovary syndrome (PCOS)
Hysterosalpingography, evidence-based diagnostic strategies, and in vitro fertilization, 318-323
9-14 Lymphocytes, endometriosis and, 137-141
Imaging studies, endometriosis diagnosis, 193-202 Matrix metalloproteinases
Immune response endometriosis pathophysiology and, 155-160
endometriosis pathophysiology and, 135-141 inhibitors, endometriosis therapy with, 213-218
environmental contaminants and endometriosis, 145-151 McCune-Albright syndrome, in pediatric patients,
Immunoglobulin superfamily, endometriosis and, 175-178 347-348
Immunomodulation, endometriosis research and, 255-260 Medical practices and procedures
Imperforate hymen, in pediatric patients, 333-335 economics studies evaluation and, 85-92
Implantation mechanisms, endometriosis pathogenesis, endometriosis therapy, 209-218
119-123 randomized clinical trials (RCT) and clinical research vs.,
Index tests, diagnostic studies and, 17-25 55-64
Infertility. See a/so In vitro fertilization/embryo transfer (IVF- systematic review and meta-analyses concerning, 95-104
ET); Subfertility Medical search engine design, evidence-based search
economics studies evaluation, 85—92 strategies, 5-8
endometriosis, medical therapy for, 209-218 Menorrhagia, abnormal bleeding in adolescents, 363-372
1-6 SEMINARS IN REPRODUCTIVE MEDICINE/VOLUME 21, NUMBER 4 2003
Menstruation cycle contraception for medically ill adolescent patients, 389-398
abnormal bleeding in adolescents, 363-372 delayed puberty and amenorrhea, 353-361
delayed puberty and amenorrhea, 353-361 Miillerian anomalies, 375-387
endometrial environment during, 159-160 pubertal developmental disorders, 339-350
matrix metalloproteinase expression during, 155-160 sexually transmitted diseases (STDs), 399-411
polycystic ovary syndrome (PCOS), adolescent patients, Pelvic examination, endometriosis diagnosis and, 193-202
301-306 Pelvic inflammatory disease (PID), in adolescent patients,
retrograde menstruation, endometriosis pathophysiology, 404-405
135-141 Pelvic pain
Mental disability, contraception for medically ill adolescent medical therapy for endometriosis and, 209-218
patients, 390-398 surgical management of endometriosis and, 223-230
Meta-analysis, evaluation of, 95-104 Pentoxfylline, endometriosis therapy using, 213-218
Metformin, prognosis studies, literature evaluation for, 27-35 Peritoneal fluid, endometriosis and function of, 184-189
Molecular targeting, medical therapy for endometriosis and, Pharmacology, polycystic ovary syndrome (PCOS) therapy,
209-218 277-282
Monocyte chemotactic protein-1 (MCP-1), endometriosis PICO (Patient-Intervention-Comparison-Outcome)
and, 137-141 research strategy, differential diagnosis and, 9-14
Monthly fecundity rate (MFR), subfertility and Polycystic ovary syndrome (PCOS)
endometriosis, 243-251 adolescent patients, 301-306
Miillerian anomalies, diagnosis and pathophysiology, cardiovascular health and, 309-314
375-387 diagnostic criteria, 267-273
abnormal bleeding in adolescents and, 367-370 hirsutism diagnosis and management, 285-291
21-hydroxylase-deficient nonclassic adrenal hyperplasia,
Natural killer cells, endometriosis pathophysiology, 135-141 differential diagnosis, 295-299
Normogonadotropic oligoamenorrheic infertility, clomiphene pharmacologic therapy, 277-282
citrate therapy, outcome predictions, 39-46 prognosis studies, literature evaluation for, 27-35
in vitro fertilization/embryo transfer (IVF-ET) and,
Obesity, polycystic ovary syndrome (PCOS) patients and, 317-323
309-314 Positional cloning techniques, endometriosis genetics, 111-117
Odds ratios, causation study guidelines, 73-83 Postoperative protocols, surgical management of
Oligomenorrhea, polycystic ovary syndrome (PCOS) therapy, endometriosis, 235-240
277-282 Precocious puberty, diagnosis and pathophysiology, 339-350
Oocyte alteration, in endometriosis, 183-189 Pregnancy, abnormal bleeding in adolescents and, 364-370
Oocyte implantation, in polycystic ovary syndrome (PCOS) Pregnancy rates, subfertility and endometriosis, 243-251
patients, 317-323 Preoperative protocols, surgical management of
Oral contraceptives endometriosis, 235-240
endometriosis therapy using, 210-218 Prepubertal reproductive anatomy, assessment strategies and
for medically ill adolescent patients, 389-398 issues, 329-337
for polycystic ovary syndrome (PCOS) patients, 288-291 Prevalence studies, subfertility and endometriosis, 243-251
Oral glucose tolerance test (OGTT), in polycystic ovary Progesterone
syndrome (PCOS) patients, 267-273, 277-283 endometriosis pathophysiology, 125-132
Outcome prediction, economics studies evaluation and, matrix metalloproteinases, endometriosis pathophysiology,
85-92 155-160
Ovarian cancer, fertility drugs and, 65-71 Progesterone receptor, endometriosis pathophysiology,
Ovarian endometriosis, surgical management of, 235-240 125-132
Ovarian function Progestogens, endometriosis therapy using, 210-218
abnormal bleeding in adolescents and, 369-371 Prognosis studies
in endometriosis, 183-189 evidence-based strategies and literature evaluation, 27-35
genetic factors in endometriosis and, 111-117 treatment outcome predictions, 39-46
polycystic ovary syndrome (PCOS) and, 268-273 Proinflammatory cytokines, matrix metalloproteinases,
Ovarian hyperstimulation syndrome, in polycystic ovary endometriosis pathophysiology, 155-160
syndrome (PCOS) patients, 317-323 Proportions, in randomized clinical trials (RCT), clinical
Ovarian suppression, endometriosis management, surgical research vs. medical practice, 55-64
therapy vs., 223-231 Proteins, endometriosis and ECM proteins, 176-178
Ovulation induction Proteomics. See a/so Genetics studies; Genomics
clomiphene citrate therapy, outcome predictions, 39-46 endometriosis pathogenesis, 119-123
ovarian cancer risk and, 65-71 Pubertal developmental disorders
delayed puberty and amenorrhea, 353-361
Pediatric gynecology polycystic ovary syndrome (PCOS) in adolescence and,
abnormal bleeding in adolescents, 363-372 301-306
assessment strategies and issues, 329-337 precocious puberty, 339-350
SUBJECT INDEX 1-7
Randomized clinical trials (RCT) Surgical procedures
causation study guidelines, 73-83 endometriosis diagnosis, 201-202
in diagnostic studies, 17-25 endometriosis management
medical practice vs. clinical research involving, 55-64 medical therapy following, 216-218
prognosis studies, literature evaluation for, 27-35 pre- and post-surgical guidelines, 235-240
systematic review and meta-analysis of, 95-104 endometriosis therapy using, 223-230
in vitro fertilization, evidence-based research, 49-54 Syphilis, in adolescent patients, 401-402
RANTES cytokine, endometriosis and, 137-141 Systematic review, evaluation of, 95-104
Reference tests, diagnostic studies and, 17-25 Systemic lupus erythematosus (SLE), contraception for
Relative risks, causation study guidelines, 73-83 medically ill adolescent patients, 390-398
Renal disease, contraception for medically ill adolescent
patients, 390-398 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD),
Research protocols endometriosis pathogenesis and, 145-151
endometriosis and subfertility, 245-251 Therapeutic strategies, evidence-based guidelines for, 5-8
endometriosis research, 255-260 Thromboembolism history, contraception for medically ill
environmental contaminants, 145-151 adolescent patients, 390-398
evidence-based research guidelines Tissue inhibitors of metalloproteinases (TIMPs),
diagnostic issues, 9-14 endometriosis and, 155-160
prognosis studies, 27-35 Transplantation theory, apoptosis and endometriosis
therapeutic options and, 5-8 pathogenesis, 165-170
in vitro fertilization trials, 49-54 Trichomoniasis, in adolescent patients, 400-401
literature evaluations Tubal factor subfertility, evidence-based diagnosis of, 9-14
ovarian cancer risk and fertility drugs, evaluation of Tumor necrosis factor (TNF)-« inhibitors, endometriosis
literature on, 65-71 therapy using, 212-218
systematic review and meta-analysis of, 95-104 Turner's syndrome, delayed puberty and, 357-361
Retrograde menstruation, endometriosis pathophysiology, Type 2 diabetes mellitus. See a/so Diabetes mellitus
135-141 Type 2 diabetes mellitus, polycystic ovary syndrome (PCOS)
Risk difference, systematic review and meta-analysis of, and, 277-282
95-104
Rokitansky-Kuster—Hauser syndrome, Miillerian anomalies, Ultrasonography, polycystic ovary syndrome (PCOS), 267-273
379-387 Urethral prolapse, in pediatric patients, 336-337
RU486, endometriosis therapy using, 211-218 Uterine function
abnormal bleeding in adolescents and, 367-370
Sampson's theory of retrograde menstruation, endometriosis in endometriosis, 183-189
pathophysiology and, 135-141 endometriosis research and receptivity studies, 255-260
Selectins, endometriosis and, 175-178 Miillerian anomalies, 375-387
Sensitivity in testing, diagnostic studies and, 17-25
Sexual abuse, pediatric gynecology and, 329-337 Vaginal septum, Miillerian anomalies, 375-387
Sexual differentiation, Miillerian anomalies, 375-387 Vaginitis, abnormal bleeding in adolescents and, 366-370
Sexually acquired hepatitis, in adolescent patients, 408-409 Vascular endothelial growth factor (VEGF), endometriosis
Sexually transmitted disease (STD), in adolescents, and, 141
399-411 Verification bias, in diagnostic studies, 21-25
Specificity in testing, diagnostic studies and, 17-25 Vertical fusion, Miillerian anomalies and, 383-387
Steroid hormones, endometriosis and, 258-260 Vulvitis, in prepubertal patients, 329-337
Steroidogenesis, endometriosis pathophysiology, 125-132 Vulvovaginitis, in prepubertal patients, 329-337
Subfertility. See a/so Infertility
endometriosis and, 243-251 Y chromosome disorders, Miillerian anomalies, 375-387